In 2025, SIA Wogen Pharm had revenue of 1.2 million EUR and profit of 193.5 thousand EUR. The company has 6 employees. Beneficial owners: Aleksandrs Mežeckis, Krists Zubačs.
| year | 2025Latest | 2024 | 2023 |
|---|---|---|---|
Revenue | 1,2m € +134.6% | 492,2k € -1.0% | 497,2k € +13.7% |
Profit | 193,5k € +239.3% | -138,9k € -2220.8% | 6,6k € +114.8% |
Assets | 289,6k € +106.7% | 140,1k € +16.9% | 119,8k € -41.1% |
Liabilities | 197,6k € -18.2% | 241,6k € +193.2% | 82,4k € -52.2% |
Equity | 92k € +190.7% | -101,5k € -371.0% | 37,4k € +21.2% |
Employees | 6 +0.0% | 6 +0.0% | 6 +20.0% |
Overall rating | A+97/100 |
Financial health | 100/100 |
Credit history | 100/100 |
Legal history | 100/100 |
Business activity | 85/100 |
| Overall risk | Low |
No risk flags | |
No tax debts | |
Positive profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| Board member | Independently | ||||
| Board member | Independently |
| Name | Changed |
|---|---|
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
| Sabiedrība ar ierobežotu atbildību "Phenylchem" | 21 January 2015 |
Project count
50
Total funding
€78 678 168
EU support
€45 000 000
| Project | Period | Role | Funding received | Status |
|---|---|---|---|---|
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
SIA Wogen Pharm is located at Rīga, Grenču iela 5, LV-1029.
In 2025, SIA Wogen Pharm had revenue of 1 154 777 EUR and profit of 193 491 EUR. Compared to previous year, revenue increased by 134.6%. View full financial report →
In 2024, SIA Wogen Pharm had an average of 6 employees. View tax history →
The beneficial owners of SIA Wogen Pharm are Aleksandrs Mežeckis and Krists Zubačs. View ownership details →
Yes, SIA Wogen Pharm is registered as an active VAT payer with VAT number LV40103487449.
In 2024, the average gross salary at SIA Wogen Pharm was approximately 824,21 € per month (net ~ 679,61 €). This is an approximate calculation. View salary details →
SIA Wogen Pharm was founded on December 2, 2011. The company has been operating for 15 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 15 years | - | 0% | |
Net revenue | 1 154 777,00 € | - | 0% | |
Profit | 193 491,00 € | - | 0% | |
Equity | 92 017,00 € | - | 0% | |
Assets | 289 618,00 € | - | 0% | |
Fixed assets | 76 962,00 € | - | 0% | |
Liquidity | 0.84 | - | 25% | |
Profitability | 16.8% | - | 40% | |
Registered capital | 30 000,00 € | - | 0% |
Annual financial report for 2025.
Annual financial report for 2024.
Annual financial report for 2023.
Annual financial report for 2022.
Annual financial report for 2021.
Annual financial report for 2020.
Registered in the Latvian company register.
| Name, surname | Birth date | Shares | Ownership rights | |
|---|---|---|---|---|
| IMUNO MEDICAL OU | - | 72 | 24.00% | |
| Aleksandrs Mežeckis | 114 | 38.00% | ||
| Krists Zubačs | 114 | 38.00% |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Aleksandrs Mežeckis | LV | ||
| Krists Zubačs | LV |